Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | PIK3CA act mut TSC2 del |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
PIK3CA act mut TSC2 del | estrogen-receptor positive breast cancer | resistant | Alpelisib | Preclinical - Cell culture | Actionable | In a preclinical study, PIK3CA-mutant, ESR1 (ER)-positive breast cancer cell lines with knockout of TSC2 were resistant to treatment with Piqray (alpelisib) in culture (PMID: 33685991). | 33685991 | |
PIK3CA act mut TSC2 del | estrogen-receptor positive breast cancer | resistant | Taselisib | Preclinical - Cell culture | Actionable | In a preclinical study, PIK3CA-mutant, ESR1 (ER)-positive breast cancer cell lines with knockout of TSC2 were resistant to treatment with Taselisib (GDC-0032) in culture (PMID: 33685991). | 33685991 |